{
  "docId": "019de517-b86e-71ab-b8dc-26b65df806cc",
  "docSlug": "744004e43ef2a69148636522635f8ce1",
  "documentTitle": "Avantor | Investor Conference Presentation Deck | 21 slides",
  "authorId": "avantor",
  "authorName": "Avantor",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 21,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de517-b86e-71ab-b8dc-26b65df806cc/15",
  "deckHref": "/decks/019de517-b86e-71ab-b8dc-26b65df806cc",
  "deckJsonHref": "/decks/019de517-b86e-71ab-b8dc-26b65df806cc.json",
  "deckAnchorHref": "/decks/019de517-b86e-71ab-b8dc-26b65df806cc#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.21,
        "w": 0.505,
        "x": 0.465,
        "y": 0.22
      },
      "kind": "chart",
      "text": "2023E TOTAL MARKET REVENUE FOR BIOLOGICS\n53% Monoclonal Antibodies\n8% GLP-1\n19% Other Protein Therapies\n3% Cell & Gene Therapies\n17% Other (e.g., mRNA)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e881d82a-1808-4d5c-9aea-deae42ccf050",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.07,
        "x": 0.88,
        "y": 0.71
      },
      "kind": "image",
      "text": "Other (e.g., mRNA) illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "117b955c-02c6-4c06-b167-034d4de15a97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.07,
        "x": 0.38,
        "y": 0.71
      },
      "kind": "image",
      "text": "Monoclonal Antibodies illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36813f3c-e7db-405f-bd91-fe2f1fbd5a76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.07,
        "x": 0.505,
        "y": 0.71
      },
      "kind": "image",
      "text": "GLP-1 illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c2d1aac-798d-49ae-971e-636394a28ef1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.07,
        "x": 0.63,
        "y": 0.71
      },
      "kind": "image",
      "text": "Other Protein Therapies illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfa08ae3-6d1c-47e5-a3f5-9bb28bbced5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.07,
        "x": 0.755,
        "y": 0.71
      },
      "kind": "image",
      "text": "Cell & Gene Therapies illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f99f648c-cfd7-4ee6-8e8d-bde2ee1bed28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.49,
        "w": 0.229,
        "x": 0.046,
        "y": 0.287
      },
      "kind": "list",
      "text": "STRONG PIPELINE OF BIOLOGIC THERAPIES\nmAbs: >30 new therapies approved in last 2 years, ~2,500 active clinical projects\nNew modalities: >2,000 active clinical projects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a2a5683-624f-42d3-9a32-71125848bd9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.12,
        "x": 0.287,
        "y": 0.296
      },
      "kind": "metric",
      "text": ">10%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70e4f99b-024c-4809-9611-2cffc5215697",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.107,
        "x": 0.296,
        "y": 0.368
      },
      "kind": "paragraph",
      "text": "Long-term market growth",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3afed77d-9f18-445e-9032-989fe7de1ac1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.046,
        "y": 0.918
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma data as of November 2023. CAGRs represent estimated revenue growth from 2018 to 2028. mAbs include traditional mAbs and recombinant antibodies. GLP-1 therapies include dual agonist therapies. Other protein therapies include insulin. Other includes nucleic acids, vaccines, etc. 1. CAGR inflated due to COVID-19 vaccine forecast uncertainty.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c04b43d3-1d92-4746-90c7-1b0d6ab979c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.679,
        "x": 0.287,
        "y": 0.62
      },
      "kind": "table",
      "text": "CAGR:\nMonoclonal Antibodies >10%\nGLP-1 >20%\nOther Protein Therapies >2%\nCell & Gene Therapies >30%\nOther (e.g., mRNA) >12%1",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a168c41c-894d-456c-a8f0-82eea82f6192",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.619,
        "x": 0.046,
        "y": 0.046
      },
      "kind": "title",
      "text": "Robust fundamentals drive double-digit long-term end market growth",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96a9fdb9-eed0-49eb-a98c-6e5a9949ee20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "80d7e01b-ee73-4411-aa9f-528c0594332c",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 13-20 provide details on growth priorities and operating model.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}